Sign up USA
Proactive Investors - Run By Investors For Investors

Axovant Sciences ‘emphasizes reboot’ with gene therapy, says Oppenheimer

Axovant expects to initiate a study of AXO-Lenti-PD in patients with advanced Parkinson's disease by the end of 2018
A woman with a doctor
The analysts maintained their Perform rating on the stock

Analysts at Oppenheimer said Axovant Sciences Ltd. (NASDAQ:AXON) emphasized its reboot with gene therapy for Parkinson’s disease.

Earlier this month, Oxford BioMedica, one of Britain’s oldest biotech companies, concluded a US$842.5m deal with Axovant Sciences to commercialize its gene therapy for Parkinson’s disease.

Called AXO-Lenti-PD, Axovant’s new project uses a harmless virus to deliver three genes key to the production of dopamine and thereby relieve the neurodegeneration that characterizes Parkinson’s disease. The company plans to start its first clinical trial this year.

“AXO-Lenti-PD is an experimental gene therapy that builds on the earlier success of ProSavin which demonstrated nominal efficacy with long-term safety in an ongoing 15-patient Ph2 study,” wrote Oppenheimer analysts Jay Olson and Silvan Tuerkcan in a note released Tuesday.

“AXO-Lenti-PD is a next-generation lentiviral vector that improves upon the efficacy of ProSavin while overcoming some of the barriers including dosing constraints imposed by the volume of administration.”

Read: Gene therapy deal to drive “pipeline transformation” for Axovant Sciences, says Oppenheimer

Axovant expects to initiate a Phase I/II dose escalation study of AXO-Lenti-PD in patients with advanced Parkinson's disease by the end of 2018.

Investment thesis

The analysts maintained their Perform rating on the stock and looked forward to additional business development, which they expected by the year-end.

“Our neutral view of Axovant Sciences is based on the failure of intepirdine in the symptomatic treatment of Alzheimer's disease and removal of valuation for dementia with Lewy bodies (DLB) from our model,” wrote the analysts.

“We see Axovant Sciences shares as approximately fairly valued for nelotanserin. Meanwhile, we believe Axovant is planning to deploy cash for business development to rebuild its pipeline.”  

The analysts said clinical-stage biopharmaceutical company, ended financial year 2018 with US$154mln in cash.

Axovant was up nearly 2% to US$4.18 in Wednesday morning trade. 

View full AXON profile View Profile

Axovant Sciences Timeline

Related Articles

consumer health segment overview
September 16 2018
The company sells clinically validated anti-ageing products for hair, skin and body.
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use